TABLE 1.
Cell Lines | Cell Viability |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medium | TNF-α |
5-FU |
Thalidomide |
||||||||||
2 μM BG | 0 μM BG | 0. μM BG5 | 1 μM BG | 2 μM BG | 0 μM BG | 0.5 μM BG | 1 μM BG | 2 μM BG | 0 μM BG | 0.5 μM BG | 1 μM BG | 2 μM BG | |
% | |||||||||||||
KBM-5 | 96 ± 2.5 | 95 ± 5.4 | 88 ± 6.6 | 64 ± 3.3* | 49 ± 3.4* | 96 ± 3.9 | 91 ± 3.7 | 71 ± 5.2* | 53 ± 5.5* | 94 ± 7.0 | 87 ± 3.4 | 70 ± 3.6* | 49 ± 4.7* |
Jurkat | 94 ± 4.3 | 95 ± 3.5 | 90 ± 3.1 | 63 ± 4.1* | 40 ± 5.7* | 97 ± 3.1 | 90 ± 3.4 | 74 ± 4.1* | 49 ± 2.2* | 96 ± 2.9 | 88 ± 3.3 | 76 ± 4.3* | 47 ± 3.5* |
U-937 | 93 ± 8.5 | 94 ± 2.9 | 84 ± 2.7* | 66 ± 2.2* | 43 ± 2.8* | 95 ± 2.5 | 89 ± 4.6 | 72 ± 4.1* | 54 ± 2.8* | 92 ± 4.9 | 83 ± 3.5* | 64 ± 5.9* | 42 ± 2.9* |
K-562 | 92 ± 5.5 | 95 ± 2.4 | 91 ± 3.2 | 56 ± 2.5* | 43 ± 3.5* | 94 ± 6.2 | 87 ± 3.2* | 59 ± 5.4* | 49 ± 3.4* | 96 ± 3.0* | 80 ± 3.9 | 63 ± 2.9* | 50 ± 4.1* |
U-266 | 95 ± 4.0 | 97 ± 3.2 | 86 ± 4.4* | 63 ± 2.9* | 47 ± 3.6* | 95 ± 1.9 | 88 ± 3.0 | 74 ± 4.7* | 59 ± 2.7* | 94 ± 5.1 | 89 ± 5.1 | 79 ± 5.8* | 56 ± 3.9* |
MM0.1S | 94 ± 6.7 | 94 ± 4.7 | 89 ± 6.8 | 74 ± 5.6* | 53 ± 3.0* | 94 ± 3.1 | 86 ± 5.9* | 79 ± 3.3* | 54 ± 3.2* | 94 ± 4.8 | 87 ± 5.4* | 74 ± 3.0* | 51 ± 3.3* |
RPMI-8226 | 92 ± 4.8 | 94 ± 4.9 | 85 ± 7.0* | 67 ± 2.0* | 44 ± 5.8* | 95 ± 2.1 | 83 ± 3.6* | 69 ± 3.0* | 51 ± 5.5* | 96 ± 3.3 | 87 ± 5.1* | 74 ± 3.0* | 52 ± 3.3* |
HL-60 | 91 ± 7.3 | 96 ± 2.3 | 87 ± 2.3* | 73 ± 2.1* | 50 ± 2.8* | 95 ± 2.3 | 88 ± 2.8 | 74 ± 2.5* | 47 ± 2.6* | 94 ± 4.6* | 84 ± 2.9 | 72 ± 3.3* | 46 ± 2.9* |
P < 0.05, significance of difference compared with control.
BG, bharangin; 5-FU, 5-fluorouracil.